CTNI-18. FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (rGBM)

BACKGROUND: Selinexor is an FDA-approved first-in-class, oral selective nuclear export inhibitor which forces nuclear retention of many tumor suppressor proteins. METHODS: We conducted a phase 2 trial of selinexor monotherapy for adults with recurrent GBM including a surgical arm to explore intratum...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Lassman, Andrew, Wen, Patrick, van den Bent, Martin, Plotkin, Scott, Walenkamp, Annemiek, Green, Adam, Wang, Hongwei, Li, Kai, Liu, Yang, Xu, Hongmei, Shah, Jatin, Kauffman, Michael, Shacham, Sharon, Mau-Soerensen, Morten
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650477/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.185
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars